Redeye comments on the outcome of AcouSort’s rights issue.
Redeye remains positive to Bredband2 despite its soft Q1 margins driven by growth efforts.
Redeye retains its view of Hanza following a Q1 report showing a relatively solid performance in a s...
Redeye retains its positive view of Teneo AI despite a Q1 report on the soft side.
Soft Q1 sales of SEK 2.9m on no machine deliveries, but 6 orders Share issue readies balance sheet f...
Sales down 7% y-o-y, headwinds from weak end-markets persist Cut '25e-'27e sales by 4-2%, EBIT by SE...
Redeye provides its comment on Mendus’ Q1 2025 report.
Sales -13% vs cons, EBIT -60%, post a strong Q4 and tough comps Guides for higher military budgets p...
EBITA SEK 271m (+3% vs. ABG, +6% vs. IR cons) We expect cons EBITA upgrades of 3-4% for '25e 15-13x ...
Redeye interviewed Freemelt’s CEO, Daniel Gidlund, about the Q1 report and recently announced orders...
Embracer becomes a shareholder in Starbreeze through a directed new share issue of 9% of the total n...
Embracer blir delägare i Starbreeze genom en riktad nyemission på 9% av de totala antalet aktier i b...
Sales +2% vs. ABGSCe, but EBITA 17% below Good customer intake, but margins weighted by investments ...
2% organic growth (ABG -2%), adj. EBITA +8% vs ABG (-16% y-o-y) Service revenues declined more than ...
Redeye gives its initial comments on the Q1 2025 report from Scandinavian ChemoTech, which was mostl...
Redeye comments on Freemelt’s Q1 results, which were softer than expected in terms of sales, while c...
Redeye comments on Hanza’s Q1 report, showing solid profitability in Main Markets while Other Market...
Redeye shares its initial thoughts on CTEK’s Q1 report, which beat our estimates across the board, s...
Sales SEK 2.9m, EBIT adj. -12m vs. cons. 7.7m and -9.
Net sales SEK 202m, -3% vs ABGSCe and Factset cons.